Sumitomo Dainippon’s Latuda (lurasidone HCl) Receives NMPA’s (CFDA) Approval for Schizophrenia

 Sumitomo Dainippon’s Latuda (lurasidone HCl) Receives NMPA’s (CFDA) Approval for Schizophrenia

Sumitomo Dainippon’s Latuda (lurasidone HCl) Receives NMPA’s (CFDA) Approval for Schizophrenia

 Shots:

  • The approval is based on P-III clinical studies results assessing Latuda (n=245) vs Placebo (n=233) in 483 patients with schizophrenia
  • The study results: PANSS @6weeks (-19.3 vs -12.7); AEs (47.0% vs 51.1%); discontinued patients (5.7% vs 6.4%); improvement in CGI-S @6 weeks; well tolerated in patients
  • Lurasidone (40/80 mg/day; flexible dose) is an antipsychotic candidate with antagonist effects for D2,5-HT2A and 5-HT7 receptors, and has received approval from the US in 2010, Canada in 2012, Switzerland in 2012, EU and Australia IN 2014 with awaited Japan approval in H1’19 for Schizophrenia

Click here to read full press release/ article | Ref: Sumitomo Dainippon | Image: Doug Lipp

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post